tbuckley/cabot-search huggingface dataset:
Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients.
Authors: Jesus Vera Aguilera, Jonas Paludo, Jarrett Failing, Robert R. McWilliams, Lisa A. Kottschade, Matthew Stephen Block, Svetomir Markovic, Roxana Stefania Dronca, Yiyi Yan
Journal: Journal of Clinical Oncology (2019)

138 Background: Clinical management of metastatic melanoma (MM) after PD-1 blockade failure remains challenging and lacks a standard of care. Chemo-immunotherapy (CIT) combinations have demonstrated favorable efficacy and safety profiles in lung cancer patients. In this study, we compared the clinical outcomes of CIT with immunotherapy or chemotherapy alone after PD-1 blockade failure. Methods: We reviewed MM patients seen at Mayo Clinic between Jan, 2012 and Jun, 2018 who failed anti-PD1 therapy and received subsequent CIT, or immune checkpoint inhibitors (ICI) or chemotherapy alone. A total of 60 patients were analyzed, the CIT cohort [n=33 (55%)] treatment consisted of carboplatin/paclitaxel (n=29), nab-paclitaxel (n=2), paclitaxel (n=1), and temozolomide (n=1). In the ICI (n=9) or chemotherapy alone cohort (n=18) [n=27 (45%)], treatment consisted of carboplatin/paclitaxel (n=11), temozolomide (n=4), nab-paclitaxel (n=3), ipilimumab/nivolumab (n=4), pembrolizumab (n=4), or nivolumab (n=1). Results: Patients in the CIT cohort had a median OS of 3.5 years (95% CI: 1.7-NR) compared to 1.8 years (95% CI: 0.9-2) in the ICI or chemotherapy alone cohort, p=0.02. The median EFS following CIT was 7.6 months (95% CI: 6-10) compared to 3.4 months (95% CI: 2.8-4.1) following either ICI or chemotherapy alone, p=0.0005. A trend towards longer median EFS with use of CIT was seen in patients with BRAF wild-type [median 9 months (95% CI: 6-12)] compared to those harboring a BRAF mutation [median 6.5 months (95% CI: 1.8-9.1), p=0.29]. Side effects were similar among both groups. Conclusions: In MM patients who have failed anti-PD-1 therapy, the CIT combination showed favorable clinical outcomes and acceptable safety profile. This regimen should be considered for MM pts in this setting who have limited treatment options. [Table: see text]
From the author:
Authors: S. Miwa
Journal: European Respiratory Journal (2011)

Serum procalcitonin level: clinical significanceTo the Editors:The study by UGAJIN et al. [1] nicely evaluates the role of procalcitonin in differentiating community-acquired pneumonia (CAP) from pulmonary tuberculosis (PTB).They have further highlighted its prognostic value in PTB.Few aspects regarding this promising biomarker need to be discussed to understand its clinical significance.Procalcitonin, a propeptide of calcitonin, is an important host response biomarker indicative of infection.In particular, it aids in assessing the severity of infection and its prognosis [2,3].Using this severity marker to differentiate two infectious diseases seems unjustified.Both the diseases can have varying degrees of severity and may also be confounded by factors such as immunocompromised status and presence of comorbidities, such as post surgery [4], trauma [5], acute exacerbations of chronic obstructive pulmonary disease and acute coronary syndrome, which can alter procalcitonin levels.Clinical presentations, pattern of radiological involvement and sputum examination still remain the gold standard, as well as cost-effective measures to differentiate PTB and CAP.Serum procalcitonin, although an important prognostic marker, may not be useful in the presence of the aforementioned comorbidities.Extensive radiological involvement, multiorgan infection, high sputum positivity and drug resistance are more reliable markers for severity of tuberculosis and poor prognosis.Serum procalcitonin measurement should be performed in selected cases of PTB where its positivity should alert the clinician to search for tubercular foci in other organs of the body.
Apologies
Authors: Juliet Aizer
Journal: Annals of Internal Medicine (2012)

Ad Libitum16 October 2012ApologiesJuliet Aizer, MD, MPHJuliet Aizer, MD, MPHFrom Hospital for Special Surgery, New York, NY 10021.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-157-8-201210160-00018 Audio Reading - “Apologies” Audio. Listen to a reading of "Apologies" by Juliet Aizer, MD, MPH. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail I hear apologies, expectations showingfor wearing clothes that take time to removenot shaving legs, not painting nailslint trapped between toeswhat I must smellthe very way your feet twist as though they hadn't brought you hereyour sweat on my exam table papersticking to everythingTake my calm my word my words as reassuranceHere I am comfortable flatteredin long pants billowing beyond the stiff length of my coatI would slip off my shoes, pull up my cuff(sometimes I haveinstantly forever to wish I had not)and so stop myself to let you see me as you wantJuliet Aizer, MD, MPHHospital for Special SurgeryNew ... Author, Article, and Disclosure InformationAffiliations: From Hospital for Special Surgery, New York, NY 10021.Current Author Address: Juliet Aizer, MD, MPH, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021; e-mail, [email protected]. PreviousarticleNextarticle Advertisement Audio Reading - “Apologies” Audio. Listen to a reading of "Apologies" by Juliet Aizer, MD, MPH. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 16 October 2012Volume 157, Issue 8Page: 596KeywordsMotivationSmellSurgerySweat ePublished: 16 October 2012 Issue Published: 16 October 2012 Copyright & PermissionsCopyright © 2012 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Learning to Modulate Transmitter Release: Themes and Variations in Synaptic Plasticity
Authors: H. Robert D.
Journal: Annual Review of Neuroscience (1993)

The brain's default mode network consists of discrete, bilateral and symmetrical cortical areas, in the medial and lateral parietal, medial prefrontal, and medial and lateral temporal cortices of the human, nonhuman primate, cat, and rodent brains. Its ...Read More
Response: Re: Impact of Classification of Hilar Cholangiocarcinomas (Klatskin Tumors) on Incidence of Intra- and Extrahepatic Cholangiocarcinoma in the United States
Authors: T. M. Welzel, K. A. McGlynn, A. W. Hsing, T. R. O'Brien, R. M. Pfeiffer
Journal: JNCI Journal of the National Cancer Institute (2007)
Decreased spleen size and increased neutrophils in patients with Felty syndrome. Effects of gold sodium thiomalate therapy
Authors: E. R. Hurd
Journal: JAMA (1976)

Three patients with Felty syndrome were treated with gold sodium thiomalate. In all three, there was an increase in total numbers of peripheral blood neutrophils and total white blood cells, as well as marked clinical improvement of the arthritic complaints. In two patients there was a marked decrease in spleen size. (<i>JAMA</i>235:2215-2217, 1976)
British problems with international messages
Journal: BMJ (2002)

reported knee pain.Thomas and colleagues (p 752) allocated patients with self reported knee pain to receive one of four options: a home based exercise programme, telephone support, exercise and telephone support, or standard care.Participants who exercised reported a 12% reduction in knee pain compared with those who did not exercise. Qualitative methods improve trial recruitmentChanging the content and delivery of information about a study can increase recruitment rates from 40% to 70%.A quality improvement report by Donovan and colleagues (p 766) shows how qualitative research methods can drive changes to the design and conduct of a trial.Embedding randomised trials in qualitative research, the authors say, may enable the most difficult evaluative questions to be tackled and improve recruitment to trials generally.
Immunophenotypic Analysis of Peripheral Blood and Bone Marrow in the Staging of B-Cell Malignant Lymphoma
Authors: Curtis A. Hanson, Paul J. Kurtin, Jerry A. Katzmann, James D. Hoyer, Chin-Yang Li, Janice M. Hodnefield, Cecelia H. Meyers, Thomas M. Habermann, Thomas E. Witzig
Journal: Blood (1999)
Control of Venereal Disease: Correction
Authors: B Euston, B Scottish, Rayner Harton
Journal: BMJ (1942)

An appointments bureau for out-patients, open from 9 a.m. to 5 p.m., came into operation at the Charing Cross Hospital on Dec. 1.Doctors are invited to telephone or write for appointments.Members of the public also may write for an appointment or apply personally at the hospital.The creation of this bureau is in line with the general policy of the big London general hospitals, which are using the appointments system in an effort to save the time of patients and to enable the hospital authorities to organize a schedule of working.The Council-of the National Association for the Prevention of Tuberculosis passed the following resolution on Oct. 19: " The Government declaration on tuberculosis is a great step forward which all interested in the eradication of this disease will most heartily welcome.The National Association desires also to con- gratulate the Minister of Health and the Secretary of State for Scotland on having brought forward this great reform and offers its whole-hearted co-operation in the practical working of the scheme.The National Association is taking the earliest possible opportunity of obtaining further information about the scheme."Dr. B. A.
A nutritional management algorithm in older patients with locally advanced esophageal cancer.
Authors: Ryan H. Moy, Shalom Sabwa, Steven Brad Maron, Marina Shcherba, Arlyn J. Apollo, Yelena Y. Janjigian, Geoffrey Yuyat Ku, William P. Tew, David H. Ilson, Elizabeth Won
Journal: Journal of Clinical Oncology (2021)

e16038 Background: Esophageal cancer primarily affects older adults, who are at highest risk for poor nutritional status due to medical comorbidities, physiological changes of aging and geriatric issues such as altered cognition and mobility. Malnutrition is correlated with poor outcomes in patients with esophageal cancer; however, standardized nutritional interventions are not commonly utilized. Therefore, we performed a feasibility study of a nutritional management algorithm with risk-based guidelines for older patients with esophageal cancer receiving chemoradiation (CRT). Methods: Elderly patients (age ≥ 65 years old) with locally advanced esophageal or gastroesophageal junction (GEJ) cancer receiving induction chemotherapy and preoperative or definitive CRT were eligible for enrollment on this single center study. Patients completed baseline nutritional assessment using the Mini Nutritional Assessment (MNA) screening scale, and patients who were at risk for malnutrition or malnourished were referred to a clinical dietician for evaluation and counseling. Nutritional status was reassessed after induction chemotherapy, and patients with severe malnutrition were to be referred for enteral feeding tube placement prior to CRT. The primary objective was to determine the feasibility of the nutritional management algorithm based on completion rates of nutritional assessment, clinical dietician referral and enteral feeding. Secondary endpoints included toxicity, functional status and quality of life assessment. Results: Twenty elderly patients with locally advanced esophageal cancer were enrolled, and fourteen patients met criteria for clinical dietitian referral based on poor baseline nutritional status. Induction chemotherapy was associated with improved dysphagia, with 92% of patients reporting improvement or resolution of symptoms. There were no patients who met criteria for enteral feeding prior to CRT based on the guidelines, and only one patient (5%) required feeding tube placement during CRT. In total, 17 patients (85%) completed the nutritional management algorithm and finished the planned treatment course. Rates of hospitalization, grade ≥2 esophagitis, grade ≥3 toxicity and early CRT discontinuation were similar between patients with normal and abnormal baseline nutrition. Conclusions: This study demonstrates that a risk-based nutritional management algorithm is feasible in elderly patients with esophageal cancer. The induction chemotherapy approach may ameliorate dysphagia, reduce the need for enteral feeding and facilitate CRT completion in this nutritionally vulnerable population. Clinical trial information: NCT02027948.
Atypical Cells of Seminal Vesicle Origin Complicating Cytologic Evaluation of Prostatic Secretions
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).
Authors: Matthew Labriola, Jason Zhu, Rajan Gupta, Shannon McCall, Jennifer Jackson, James R White, Elizabeth Weingartner, Eric Kong, Peter Simone, Eniko Papp, Kelly Gerding, John Simmons, Daniel J. George, Tian Zhang
Journal: Journal of Clinical Oncology (2019)

589 Background: ICIs have revolutionized treatment for mRCC; however there are limited predictive biomarkers for response to ICIs. PD-L1 status is still controversial demonstrating little predictive utility in mRCC. TMB is predictive for response to ICIs in melanoma and non-small cell lung cancer (NSCLC), but has not been validated in mRCC. Here, we assess the correlations between TMB and PD-L1 status with outcomes to ICI treatment in mRCC. Methods: 34 patients (pts) with mRCC who had previously received ICI therapy at Duke Cancer Institute were identified. Tumor samples were retrospectively evaluated using a Personal Genome Diagnostics Assay for somatic variants across &gt; 500 genes, as well as TMB and microsatellite status. Tumor samples were also analyzed with the Dako 28-8 PD-L1 IHC assay. Deidentified clinical information was extracted from the medical record and tumor response was evaluated based on RECIST criteria. Results: Pts were grouped by overall response following ICI therapy into either progressive disease (“PD”, n = 18) or disease control group (“DC”, n = 16), defined as either stable disease, partial response, or complete response. Pts displayed a TMB range from 0.36 to 12.24 mutations/Mb with a mean score of 2.83 muts/Mb, with no significant difference between the PD and DC groups (mean 3.01 muts/Mb vs. 2.63 muts/Mb, p &gt; 0.05). 9 of 32 evaluable samples were PD-L1 positive, with 4 in the PD group and 5 in the DC group. Notably, the DC group displayed a significant enrichment of mutations in genes affiliated with DNA repair (including BRCA1, BRCA2, FANCA, FANCB, FANCG, FANCM, MSH3, MSH6, RAD50, RAD51C, RAD51D, RAD54B, RECQL4, and SLX4; p = 0.0444). Conclusions: Overall, in this mRCC cohort, neither TMB nor PD-L1 correlated with patient outcomes or with ICI response. Furthermore, high TMB was not significantly associated with PD-L1 expression within the samples. The higher frequency of mutations in DNA repair genes in the DC group suggests potential use as a predictive signature for ICI response, warranting future prospective studies.
THE PRACTICAL OBJECT OF ORGANIZATION.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Incomplete Disclosures
Authors: Paul Young
Journal: JAMA (2020)

Ian H. de Boer, MD, MS; Leila R. Zelnick, PhD; John Ruzinski, BS; Georgina Friedenberg, MPH; Julie Duszlak, BS; Vadim Y. Bubes, PhD; Andrew N. Hoofnagle, MD, PhD; Ravi Thadhani, MD, MPH; Robert J. Glynn, PhD, ScD; Julie E. Buring, ScD; Howard D. Sesso, ScD, MPH; JoAnn E. Manson, MD, DrPH
HIV infection as leading cause of death among young adults in US cities and states
Authors: R. M. Selik
Journal: JAMA (1993)

<h3>Objective.</h3> —To describe the extent to which human immunodeficiency virus (HIV) infection has become the leading cause of death among young adults (25 to 44 years of age) in US states and cities of at least 100000 population. <h3>Design.</h3> —Analysis of underlying causes of death using national vital statistics for 1990 by state and city. Deaths caused by HIV were defined as those with underlying cause assigned a code number of 042,043, or 044, as established by the National Center for Health Statistics. <h3>Results.</h3> —Infection with HIV was the leading cause of death among young men in five states, causing 29% of their deaths in New York, 28% in New Jersey, 24% in California and Florida, and 16% in Massachusetts. Among young women, HIV was not the leading cause of death in any state. Among young men, HIV infection was the leading cause of death in 64 cities, with the proportion of deaths due to HIV ranging from 16% in Bridgeport, Conn, to 61% in San Francisco, Calif. Among young women, HIV infection was the leading cause of death in nine cities, with the proportion of deaths due to HIV ranging from 15% in Baltimore, Md, to 43% in Newark, NJ. <h3>Conclusion.</h3> —In many US communities, HIV infection is the leading cause of death among young men and women, causing a large proportion of deaths in this age group. (<i>JAMA</i>. 1993;269:2991-2994)
Comprehensive cytogenetic study by spectral karyotyping on blastic natural killer cell leukemia/lymphoma
Authors: Naoto Jyoko, Junya Kuroda, Shinya Kimura, Yutaka Kobayashi, Toshikazu Yoshikawa
Journal: American Journal of Hematology (2002)

A 32-year-old male presented with fever, mental status changes, renal dysfunction, cytopenias and hemolysis.His platelet count was 14,000/lL, hemoglobin 5.7 g/dL and LDH 2,636 U/L.He was diagnosed with thrombotic thrombocytopenic purpura (TTP) and also found to be HIV positive on admission.TTP was con®rmed by a low von Willebrand factor-cleaving protease level, the gold standard test for TTP, which was 10±15%.No protease-speci®c antibody was detected.Treatment of this patient consisted of 23 plasmapheresis procedures and trials of vincristine and dextran-70.Despite therapy, the patient remained anemic and thrombocytopenic, though his mental status and renal abnormalities improved.Highly active anti-retroviral therapy (HAART) consisting of efavirenz, 3TC, and d4T was started.Only after plasma exchanges were discontinued and HAART was instituted did the cytopenias resolve.He continued to improve following discharge, and platelet count was 206,000/lL and hemoglobin, 12.5 g/dL one month after the initiation of HAART.Am.
Recent government decision refocuses attention on several cases of alleged scientific misconduct
Authors: C. Marwick
Journal: JAMA (1993)

A GOVERNMENT appeals board has overruled findings of scientific misconduct by a Cleveland (Ohio) Clinic Foundation scientist, Rameshwar K. Sharma, MD, made by another government entity. The misconduct charge involved making two false statements in grant applications to the National Institutes of Health (NIH), Bethesda, Md. Handing down its decision, the appeals board said that the Office of Research Integrity had "failed to carry its burden of proving scientific misconduct by a preponderance of the evidence as to either grant application." The panel's decision is the first to be made under a revised system of handling misconduct cases set up last summer by James O. Mason, MD, then Assistant Secretary for Health. One of the changes Mason made was to allow scientists charged with misconduct the right of appeal to an independent adjudicatory body (<i>JAMA</i>. 1992;268:848). Under this system, a tribunal held a hearing on the Sharma case last May.
Locum Tenens.
Authors: None M.D.
Journal: JAMA (1897)

December26, 1896. <h3>To the Editor:</h3> —Please answer the following question: Dr. A. was engaged to attend Mrs. Blank in confinement. When labor came on the husband telephoned for the Doctor, but received a reply from the residence that he was absent from town for the night. The husband then called Dr. B., who responded and delivered the woman. The next morning Dr. B. called on Dr. A. and told him that Mrs. Blank had been confined during his absence. Which physician should properly look after the case during the puerperium? The two physicians are the best of friends and enjoy the easiest professional intercourse. Respectfully, Answer: Dr. A. should attend the case. Dr. B. was simply<i>locum tenens</i>.
Retraction: Sudbø J et al. DNA Content as a Prognostic Marker in Patients with Oral Leukoplakia. N Engl J Med 2001;344:1270-8 and Sudbø J et al. The Influence of Resection and Aneuploidy on Mortality in Oral Leukoplakia. N Engl J Med 2004;350:1405-13
Authors: Gregory D. Curfman, Stephen Morrissey, Jeffrey M. Drazen
Journal: New England Journal of Medicine (2006)

Editorial from The New England Journal of Medicine — Retraction: Sudbø J et al. DNA Content as a Prognostic Marker in Patients with Oral Leukoplakia. N Engl J Med 2001;344:1270-8 and Sudbø J et al. The Influence of Resection and Aneuploidy on Mortality in Oral Leukoplakia. N Engl J Med 2004;350:1405-13